Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Gastroenterology. 2012 Jan 4;142(4):844–854.e4. doi: 10.1053/j.gastro.2011.12.041

Figure 7.

Figure 7

(A) Oral doses of 10 mg kg−1 and 1.0 mg kg−1 tegaserod significantly reduced the VMR at distension pressures of 30 mm Hg and greater (*P < .05 vs control; **P < .01 vs control; ***P < .001 vs vehicle; n = 6–7). (C) Oral naronapride decreased the VMR at doses of 0.1 mg kg−1 and higher, with a maximal effect at 1 mg kg−1. Intracolonic administration of (B) tegaserod and (D) naronapride decreased the VMR to CRD at doses of 0.1 and 1.0 mg kg−1 (n = 5–6). This effect was inhibited by the 5-HT4R antagonist, GR113808 (1.0 mg kg−1), administered intracolonically (dashed lines; n = 5–6).